Scientists are reprogramming Salmonella bacteria, best known for causing food poisoning, into a potential cancer treatment. Researchers have engineered a weakened strain of Salmonella typhimurium that can infiltrate tumours, self-destruct, and release immune-stimulating proteins to flip the tumour environment from suppressive to hostile. As Energy Reporters explained, the bacterium effectively acts as a “living drug,” producing proteins inside the tumour before breaking apart in synchrony, unleashing signals that call in immune cells.
This approach builds on earlier work showing that Salmonella can be programmed with “synchronised lysis circuits.” In 2016, researchers writing in Nature described how engineered bacteria could colonise tumours in mice, then rupture at set intervals to deliver therapeutic payloads directly to cancerous tissue. By exploiting the low-oxygen, nutrient-rich conditions inside tumours, scientists can use bacteria to do what many drugs struggle to achieve: target cancer cells without harming surrounding healthy tissue.
How it works, and the strategy behind the engineering
The key is precision. The reprogrammed bacteria are weakened so they no longer cause disease but retain the ability to thrive in tumour microenvironments. Once they accumulate, they release immune-activating molecules like LIGHT, which can drive the formation of tertiary lymphoid structures, or immune “hubs” inside the tumour. A study covered by New Atlas found that this process shrank colorectal cancers in mice by recruiting T-cells and B-cells into the tumour core, making it more vulnerable to attack.
Other research has gone further. Teams have engineered Salmonella to deprive tumours of nutrients by overproducing enzymes like L-methioninase, or to deliver bacterial proteins such as flagellin that supercharge the body’s immune response. The idea is that the bacterial chassis can be modified again and again to deliver different cancer-fighting payloads, depending on the type of tumour.
Bacterial therapy offers some unique advantages. Because the microbes selectively colonise tumours, they can concentrate treatment where it’s needed most, reducing damage to healthy tissues. They also turn tumours from “cold” immune deserts into “hot” battlegrounds, which could make cancers far more responsive to checkpoint inhibitors and other immunotherapies. The adaptability of the system means scientists could, in theory, reprogramme the bacteria to target a wide range of cancers.
But there are major risks. Even weakened strains of Salmonella carry the danger of uncontrolled infection or sepsis. The immune response, while helpful against tumours, could also trigger dangerous inflammation. And what works in mice doesn’t always translate neatly to humans. As the World Health Organization has cautioned, innovative therapies like bacterial engineering require rigorous safety protocols before they reach human trials.
The future of “living drugs”
The next stage will be to refine kill-switches, improve safety controls, and test whether colonisation works reliably in human tumours. Scientists are also exploring combinations: pairing bacteria with chemotherapy, radiation, or CAR-T therapies to maximise the effect. If the results hold up, this research could herald a new class of “living medicines,” where microbes act as programmable allies in the fight against cancer.
What was once a cause of food poisoning could one day be a front-line treatment. The idea that Salmonella might save lives instead of threatening them shows how far synthetic biology has come, and how much potential lies ahead if these therapies prove safe and effective.